Company

Corporate Overview and Mission

The discovery of suitable lead structures for new drugs from an inexhaustibly large reservoir of theoretically possible compounds (order of magnitude: 10¹⁰⁰) is one of the biggest challenges for the pharmaceutical industry. The search for the "needle in the haystack" (a drug candidate) nowadays is often performed by using high throughput screening (HTS), neglecting that even high-throughput methods can only cover an extremely small fraction of all possibilities.

Inte:Ligand has developed methods to create new drug candidates and assess their development risks in a rational way.

Our Business Concept

The business concept of Inte:Ligand is targeted on offering new technologies to the pharmaceutical industry in order to make drug development faster, more efficient and more economical. Inte:Ligand is developing novel integrated software solutions, which will revolutionize lead structure discovery and optimization and, in addition, will permit the analysis of potential side effect and risks.

Thus the R&D processes at the beginning of drug development (early discovery phase) are substantially optimized and accelerated, as well as the dropout rate and thus the risk reduced. Therefore through the know-how and the tools of Inte:Ligand, we enable our customers to substantially reduce their drug development costs.